Public Company Edition: There was just one initial public offering during the past two weeks, but another biotech-focused SPAC went public and Gingko Bioworks announced a high-value SPAC merger. Also, Insmed and Dynavax offerings led recent public company financings.

The ABV 8 fund will invest $15m to $30m per company across the range from start-ups to development-stage companies.

Private Company Edition: The venture capital firm said it will back biopharma, diagnostics and other opportunities in health care. In addition to the Design and TScan mega-rounds, Verve raised $94m, Vera garnered $80m and Ixaka (formerly Rexgenero) closed a £40m ($54.7m) financing. 

The German drugmaker is seeing growing demand for its services from peers in the pharma world that are looking to develop vaccines to tackle the COVID-19 pandemic.